Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × Pharmacogenomic Variants × Clear all
NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Stanford University

Phase 2 Completed
22 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡